Monte Rosa Therapeutics (GLUE) Enterprise Value (QoQ) (2020 - 2026)
Monte Rosa Therapeutics (GLUE) Enterprise Value (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -422.08% |
| Dec 31, 2025 | 67.66% |
| Sep 30, 2025 | -33.49% |
| Jun 30, 2025 | -283.11% |
| Mar 31, 2025 | 79.39% |
| Dec 31, 2024 | -203.38% |
| Sep 30, 2024 | -15.37% |
| Jun 30, 2024 | -9.12% |
| Mar 31, 2024 | 22.13% |
| Dec 31, 2023 | -116.92% |
| Sep 30, 2023 | -25.58% |
| Jun 30, 2023 | 10.95% |
| Mar 31, 2023 | 5.49% |
| Dec 31, 2022 | 50.71% |
| Sep 30, 2022 | -9.35% |
| Jun 30, 2022 | 25.05% |
| Mar 31, 2022 | 60.04% |
| Dec 31, 2021 | 5.71% |
| Sep 30, 2021 | -2.79% |
| Jun 30, 2021 | -111.99% |